 Uwe Christians
Concepts (1113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunosuppressive Agents | 133 | 2024 | 858 | 12.190 |
Why?
| | Sirolimus | 59 | 2019 | 270 | 6.810 |
Why?
| | Cyclosporine | 74 | 2019 | 263 | 6.570 |
Why?
| | Tandem Mass Spectrometry | 38 | 2025 | 525 | 5.460 |
Why?
| | Tacrolimus | 46 | 2019 | 193 | 4.420 |
Why?
| | Chromatography, High Pressure Liquid | 68 | 2024 | 584 | 4.380 |
Why?
| | Drug Monitoring | 23 | 2020 | 214 | 3.750 |
Why?
| | Kidney Transplantation | 46 | 2018 | 669 | 3.190 |
Why?
| | Chromatography, Liquid | 26 | 2024 | 424 | 2.600 |
Why?
| | Mycophenolic Acid | 15 | 2017 | 110 | 2.420 |
Why?
| | Metabolomics | 18 | 2022 | 652 | 2.340 |
Why?
| | Kidney | 25 | 2022 | 1382 | 2.300 |
Why?
| | Microsomes, Liver | 19 | 2019 | 87 | 2.120 |
Why?
| | Everolimus | 25 | 2020 | 88 | 2.080 |
Why?
| | Mass Spectrometry | 34 | 2021 | 717 | 1.860 |
Why?
| | Biomarkers | 28 | 2025 | 3968 | 1.730 |
Why?
| | Graft Rejection | 26 | 2019 | 598 | 1.430 |
Why?
| | Liver Transplantation | 28 | 2018 | 833 | 1.350 |
Why?
| | Proteomics | 18 | 2024 | 1053 | 1.320 |
Why?
| | Dronabinol | 14 | 2024 | 203 | 1.290 |
Why?
| | Cannabis | 12 | 2024 | 461 | 1.140 |
Why?
| | Plant Extracts | 6 | 2024 | 198 | 1.140 |
Why?
| | Oxidative Stress | 17 | 2019 | 1261 | 1.080 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.080 |
Why?
| | Cytochrome P-450 CYP3A | 20 | 2021 | 88 | 1.060 |
Why?
| | Rats | 62 | 2024 | 5470 | 1.050 |
Why?
| | Organ Transplantation | 10 | 2019 | 228 | 1.050 |
Why?
| | Cannabinoids | 8 | 2024 | 154 | 1.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2017 | 427 | 1.040 |
Why?
| | Cannabidiol | 6 | 2024 | 108 | 1.030 |
Why?
| | Hallucinogens | 6 | 2024 | 102 | 1.030 |
Why?
| | Humans | 235 | 2025 | 129527 | 1.020 |
Why?
| | Dried Blood Spot Testing | 3 | 2020 | 95 | 1.010 |
Why?
| | Pravastatin | 9 | 2021 | 40 | 1.000 |
Why?
| | Hydrocortisone | 3 | 2025 | 306 | 0.960 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 8 | 2019 | 180 | 0.960 |
Why?
| | Reproducibility of Results | 27 | 2025 | 3081 | 0.960 |
Why?
| | Immunoassay | 3 | 2020 | 108 | 0.930 |
Why?
| | Cytochrome P-450 Enzyme System | 17 | 2019 | 151 | 0.920 |
Why?
| | Drug Interactions | 26 | 2017 | 397 | 0.900 |
Why?
| | Metabolome | 5 | 2022 | 338 | 0.890 |
Why?
| | Animals | 120 | 2025 | 35334 | 0.880 |
Why?
| | Mitochondria | 6 | 2017 | 876 | 0.850 |
Why?
| | Proteome | 5 | 2017 | 440 | 0.850 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 7 | 2022 | 254 | 0.840 |
Why?
| | Drugs, Generic | 4 | 2019 | 21 | 0.810 |
Why?
| | Lovastatin | 7 | 2013 | 37 | 0.810 |
Why?
| | Intestinal Mucosa | 7 | 2017 | 593 | 0.790 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2015 | 429 | 0.780 |
Why?
| | Nucleotides | 2 | 2017 | 119 | 0.770 |
Why?
| | Magnetic Resonance Spectroscopy | 18 | 2017 | 541 | 0.770 |
Why?
| | Male | 136 | 2025 | 63586 | 0.760 |
Why?
| | Isoprostanes | 4 | 2012 | 15 | 0.750 |
Why?
| | Biological Availability | 12 | 2019 | 147 | 0.740 |
Why?
| | Pharmaceutical Preparations | 3 | 2017 | 168 | 0.740 |
Why?
| | United States Food and Drug Administration | 3 | 2020 | 195 | 0.740 |
Why?
| | Cortisone | 1 | 2021 | 11 | 0.740 |
Why?
| | TOR Serine-Threonine Kinases | 7 | 2016 | 393 | 0.720 |
Why?
| | Pregnanolone | 1 | 2021 | 33 | 0.720 |
Why?
| | Female | 112 | 2025 | 68650 | 0.700 |
Why?
| | Cyclosporins | 18 | 2001 | 76 | 0.700 |
Why?
| | Transplant Recipients | 4 | 2019 | 163 | 0.700 |
Why?
| | Urine | 2 | 2017 | 60 | 0.690 |
Why?
| | Energy Metabolism | 17 | 2022 | 864 | 0.680 |
Why?
| | Estrogen Receptor beta | 2 | 2012 | 37 | 0.670 |
Why?
| | Dinoprost | 6 | 2019 | 44 | 0.660 |
Why?
| | Progesterone | 1 | 2021 | 244 | 0.650 |
Why?
| | Dose-Response Relationship, Drug | 25 | 2024 | 2013 | 0.640 |
Why?
| | Therapeutic Equivalency | 6 | 2019 | 30 | 0.640 |
Why?
| | Limit of Detection | 11 | 2024 | 83 | 0.630 |
Why?
| | Pharmacology | 1 | 2019 | 9 | 0.630 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 6 | 2004 | 48 | 0.620 |
Why?
| | Tissue Distribution | 12 | 2019 | 315 | 0.610 |
Why?
| | Signal Transduction | 11 | 2017 | 4916 | 0.600 |
Why?
| | Factor Xa Inhibitors | 1 | 2020 | 170 | 0.600 |
Why?
| | Models, Biological | 9 | 2021 | 1717 | 0.600 |
Why?
| | Brain | 13 | 2019 | 2675 | 0.590 |
Why?
| | Therapies, Investigational | 1 | 2017 | 17 | 0.560 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.560 |
Why?
| | Menopause | 3 | 2019 | 297 | 0.550 |
Why?
| | Toxicity Tests | 1 | 2017 | 29 | 0.550 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2024 | 572 | 0.550 |
Why?
| | Intestine, Small | 5 | 2006 | 151 | 0.540 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 31 | 0.540 |
Why?
| | Rats, Wistar | 16 | 2024 | 443 | 0.540 |
Why?
| | Anticoagulants | 2 | 2020 | 637 | 0.530 |
Why?
| | Myocardium | 4 | 2017 | 981 | 0.510 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.510 |
Why?
| | Helminth Proteins | 1 | 2016 | 23 | 0.500 |
Why?
| | Choline | 3 | 2022 | 122 | 0.500 |
Why?
| | Lipid Metabolism | 2 | 2017 | 500 | 0.500 |
Why?
| | Kidney Diseases | 3 | 2018 | 382 | 0.490 |
Why?
| | Hemorrhage | 1 | 2020 | 680 | 0.490 |
Why?
| | Analgesics, Opioid | 8 | 2021 | 919 | 0.490 |
Why?
| | Fishes | 1 | 2016 | 94 | 0.480 |
Why?
| | Endocannabinoids | 4 | 2024 | 53 | 0.480 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 312 | 0.470 |
Why?
| | Clinical Laboratory Techniques | 1 | 2015 | 94 | 0.460 |
Why?
| | Oxidoreductases, N-Demethylating | 6 | 2004 | 16 | 0.460 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 186 | 0.460 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1842 | 0.450 |
Why?
| | Drug-Eluting Stents | 6 | 2013 | 74 | 0.440 |
Why?
| | Amino Acids | 3 | 2016 | 487 | 0.440 |
Why?
| | Fingolimod Hydrochloride | 2 | 2024 | 39 | 0.440 |
Why?
| | Adult | 61 | 2025 | 35505 | 0.440 |
Why?
| | Premature Birth | 3 | 2025 | 317 | 0.440 |
Why?
| | Multiprotein Complexes | 1 | 2015 | 154 | 0.430 |
Why?
| | Polyenes | 8 | 1998 | 16 | 0.430 |
Why?
| | Hydroxyurea | 1 | 2013 | 34 | 0.420 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2013 | 38 | 0.420 |
Why?
| | Molecular Structure | 10 | 2014 | 482 | 0.420 |
Why?
| | Metabolic Clearance Rate | 9 | 2019 | 115 | 0.420 |
Why?
| | Anticholesteremic Agents | 4 | 2007 | 146 | 0.420 |
Why?
| | Protein Kinases | 4 | 2017 | 314 | 0.410 |
Why?
| | Piperazines | 4 | 2009 | 339 | 0.410 |
Why?
| | Coated Materials, Biocompatible | 3 | 2020 | 59 | 0.400 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 92 | 0.400 |
Why?
| | Pyrimidines | 4 | 2014 | 458 | 0.400 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.390 |
Why?
| | Heart Transplantation | 8 | 2017 | 722 | 0.390 |
Why?
| | Liver | 14 | 2023 | 1836 | 0.390 |
Why?
| | Administration, Oral | 12 | 2025 | 783 | 0.390 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2012 | 28 | 0.390 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2021 | 836 | 0.380 |
Why?
| | In Vitro Techniques | 18 | 2017 | 1091 | 0.380 |
Why?
| | Vasomotor System | 1 | 2012 | 44 | 0.380 |
Why?
| | Middle Aged | 47 | 2021 | 31087 | 0.380 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 2044 | 0.380 |
Why?
| | Hypoxia | 6 | 2024 | 1081 | 0.370 |
Why?
| | Lung Transplantation | 8 | 2000 | 290 | 0.370 |
Why?
| | Macrophages, Alveolar | 4 | 2016 | 389 | 0.370 |
Why?
| | Area Under Curve | 9 | 2021 | 306 | 0.350 |
Why?
| | Swine | 15 | 2017 | 760 | 0.350 |
Why?
| | Neonatal Abstinence Syndrome | 2 | 2021 | 23 | 0.350 |
Why?
| | Microsomes | 5 | 1998 | 35 | 0.350 |
Why?
| | Artifacts | 1 | 2011 | 127 | 0.350 |
Why?
| | Acetaminophen | 1 | 2013 | 248 | 0.340 |
Why?
| | Drug Therapy, Combination | 17 | 2017 | 1037 | 0.340 |
Why?
| | Hydroxylation | 5 | 2019 | 42 | 0.330 |
Why?
| | Rats, Sprague-Dawley | 18 | 2023 | 2393 | 0.330 |
Why?
| | Cardiovascular Agents | 4 | 2020 | 157 | 0.320 |
Why?
| | Calcineurin Inhibitors | 6 | 2014 | 69 | 0.320 |
Why?
| | Graft Survival | 6 | 2018 | 514 | 0.320 |
Why?
| | Disease Models, Animal | 12 | 2024 | 4073 | 0.320 |
Why?
| | Phosphates | 5 | 2012 | 181 | 0.320 |
Why?
| | Drug Approval | 1 | 2010 | 86 | 0.320 |
Why?
| | Pain, Postoperative | 3 | 2018 | 244 | 0.320 |
Why?
| | Young Adult | 23 | 2025 | 12438 | 0.320 |
Why?
| | Cell Proliferation | 10 | 2020 | 2367 | 0.320 |
Why?
| | Isoniazid | 2 | 2006 | 63 | 0.310 |
Why?
| | Lidocaine | 2 | 2023 | 41 | 0.310 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 895 | 0.310 |
Why?
| | Bile | 7 | 1992 | 34 | 0.310 |
Why?
| | Theophylline | 2 | 2020 | 68 | 0.310 |
Why?
| | Diltiazem | 3 | 1997 | 28 | 0.300 |
Why?
| | Glucose | 7 | 2017 | 996 | 0.300 |
Why?
| | Marijuana Smoking | 3 | 2021 | 247 | 0.300 |
Why?
| | Pregnancy | 13 | 2025 | 6412 | 0.300 |
Why?
| | Flavanones | 1 | 2008 | 4 | 0.300 |
Why?
| | Drugs, Chinese Herbal | 1 | 2008 | 15 | 0.300 |
Why?
| | Paclitaxel | 3 | 2020 | 217 | 0.300 |
Why?
| | Medical Marijuana | 2 | 2021 | 111 | 0.300 |
Why?
| | Child | 25 | 2022 | 20932 | 0.300 |
Why?
| | Neurons | 3 | 2019 | 1509 | 0.290 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 68 | 0.290 |
Why?
| | Prospective Studies | 16 | 2021 | 7150 | 0.290 |
Why?
| | Adolescent | 29 | 2021 | 20409 | 0.290 |
Why?
| | Double-Blind Method | 10 | 2024 | 1873 | 0.290 |
Why?
| | Liver Function Tests | 5 | 2025 | 112 | 0.280 |
Why?
| | Time Factors | 18 | 2022 | 6530 | 0.280 |
Why?
| | Calcium Channel Blockers | 3 | 1997 | 160 | 0.280 |
Why?
| | Biotransformation | 18 | 2021 | 67 | 0.280 |
Why?
| | Buprenorphine | 2 | 2021 | 162 | 0.280 |
Why?
| | Naltrexone | 1 | 2008 | 87 | 0.280 |
Why?
| | Angioplasty, Balloon | 3 | 2020 | 92 | 0.270 |
Why?
| | Drug Stability | 4 | 2013 | 160 | 0.270 |
Why?
| | Lipase | 2 | 2020 | 66 | 0.270 |
Why?
| | Pyridostigmine Bromide | 1 | 2006 | 5 | 0.270 |
Why?
| | Half-Life | 8 | 2019 | 162 | 0.260 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 30 | 0.260 |
Why?
| | Tachycardia | 1 | 2006 | 57 | 0.260 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2006 | 43 | 0.260 |
Why?
| | Reactive Oxygen Species | 4 | 2010 | 591 | 0.260 |
Why?
| | Glomerular Filtration Rate | 8 | 2022 | 711 | 0.260 |
Why?
| | Macaca fascicularis | 13 | 2008 | 63 | 0.250 |
Why?
| | Drug Carriers | 2 | 2020 | 121 | 0.250 |
Why?
| | Mice | 19 | 2025 | 16973 | 0.250 |
Why?
| | Substance Abuse Detection | 3 | 2022 | 79 | 0.250 |
Why?
| | Drug Delivery Systems | 4 | 2020 | 337 | 0.250 |
Why?
| | Regression Analysis | 5 | 2020 | 994 | 0.250 |
Why?
| | Dogs | 6 | 2025 | 385 | 0.250 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2024 | 46 | 0.250 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3181 | 0.250 |
Why?
| | Mice, Knockout | 6 | 2019 | 2887 | 0.250 |
Why?
| | Cross-Over Studies | 5 | 2017 | 522 | 0.250 |
Why?
| | Epilepsy | 2 | 2020 | 322 | 0.240 |
Why?
| | Corticosterone | 2 | 2024 | 220 | 0.240 |
Why?
| | Isomerism | 2 | 2024 | 54 | 0.240 |
Why?
| | Heptanoic Acids | 2 | 2007 | 63 | 0.240 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 68 | 0.240 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2019 | 367 | 0.240 |
Why?
| | Catheters | 2 | 2017 | 70 | 0.240 |
Why?
| | Infant, Newborn | 12 | 2024 | 5769 | 0.240 |
Why?
| | Drug Synergism | 7 | 2014 | 370 | 0.240 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.230 |
Why?
| | Cholic Acid | 1 | 2024 | 5 | 0.230 |
Why?
| | Mitragyna | 1 | 2024 | 5 | 0.230 |
Why?
| | Alkaloids | 1 | 2024 | 28 | 0.230 |
Why?
| | Ketorolac | 2 | 2017 | 20 | 0.230 |
Why?
| | Clemastine | 1 | 2024 | 1 | 0.230 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 825 | 0.230 |
Why?
| | Diphosphonates | 1 | 2025 | 58 | 0.230 |
Why?
| | Benzylidene Compounds | 2 | 2017 | 20 | 0.220 |
Why?
| | Animals, Newborn | 3 | 2024 | 827 | 0.220 |
Why?
| | Pyrroles | 2 | 2007 | 201 | 0.220 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1684 | 0.220 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.220 |
Why?
| | Mice, Inbred C57BL | 10 | 2024 | 5468 | 0.220 |
Why?
| | Acyl-CoA Dehydrogenases | 1 | 2024 | 12 | 0.220 |
Why?
| | Cholesterol | 5 | 2013 | 399 | 0.220 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2004 | 83 | 0.220 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 25 | 0.220 |
Why?
| | Gestational Age | 3 | 2022 | 875 | 0.220 |
Why?
| | Anti-HIV Agents | 3 | 2013 | 757 | 0.220 |
Why?
| | Kinetics | 8 | 2013 | 1641 | 0.220 |
Why?
| | Cell Line | 7 | 2017 | 2774 | 0.220 |
Why?
| | Morphine | 2 | 2018 | 138 | 0.220 |
Why?
| | Glycerides | 1 | 2024 | 20 | 0.220 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 46 | 0.220 |
Why?
| | Protease Inhibitors | 1 | 2004 | 106 | 0.220 |
Why?
| | Birth Weight | 2 | 2024 | 504 | 0.220 |
Why?
| | Arachidonic Acids | 1 | 2024 | 59 | 0.210 |
Why?
| | Deoxycytidine | 1 | 2025 | 163 | 0.210 |
Why?
| | Child, Preschool | 12 | 2024 | 10499 | 0.210 |
Why?
| | Niacinamide | 1 | 2024 | 75 | 0.210 |
Why?
| | Leukemia | 2 | 2020 | 230 | 0.210 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2006 | 245 | 0.210 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 484 | 0.210 |
Why?
| | Macrolides | 1 | 2003 | 60 | 0.210 |
Why?
| | Mixed Function Oxygenases | 5 | 2001 | 41 | 0.200 |
Why?
| | Adiponectin | 1 | 2025 | 236 | 0.200 |
Why?
| | Transplantation | 4 | 2016 | 31 | 0.200 |
Why?
| | Glycolysis | 4 | 2012 | 313 | 0.200 |
Why?
| | Neurofibromatosis 1 | 2 | 2015 | 50 | 0.200 |
Why?
| | Analgesia | 1 | 2024 | 104 | 0.200 |
Why?
| | Hepatitis C | 1 | 2005 | 244 | 0.200 |
Why?
| | Blotting, Western | 8 | 2012 | 1199 | 0.190 |
Why?
| | White Matter | 1 | 2024 | 135 | 0.190 |
Why?
| | Rats, Inbred Lew | 11 | 2012 | 111 | 0.190 |
Why?
| | Glutamine | 3 | 2012 | 100 | 0.190 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 84 | 0.190 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 549 | 0.190 |
Why?
| | Kidney Failure, Chronic | 4 | 2017 | 546 | 0.190 |
Why?
| | Pharmacogenetics | 3 | 2010 | 172 | 0.190 |
Why?
| | Hepatectomy | 2 | 2023 | 212 | 0.190 |
Why?
| | Aminophylline | 2 | 2020 | 10 | 0.190 |
Why?
| | Heart Rate, Fetal | 1 | 2021 | 21 | 0.190 |
Why?
| | Homocysteine | 2 | 2019 | 152 | 0.190 |
Why?
| | Pilot Projects | 8 | 2023 | 1594 | 0.180 |
Why?
| | Prostaglandins | 2 | 2019 | 94 | 0.180 |
Why?
| | Biological Transport, Active | 5 | 2006 | 78 | 0.180 |
Why?
| | TRPP Cation Channels | 1 | 2022 | 79 | 0.180 |
Why?
| | Kynurenine | 2 | 2022 | 113 | 0.180 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2018 | 168 | 0.180 |
Why?
| | Transplantation, Heterologous | 3 | 2006 | 190 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 175 | 0.180 |
Why?
| | Fetal Development | 2 | 2021 | 287 | 0.180 |
Why?
| | Hypoxia-Ischemia, Brain | 2 | 2020 | 33 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 535 | 0.180 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 118 | 0.180 |
Why?
| | Transplantation, Homologous | 8 | 2018 | 402 | 0.180 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 796 | 0.180 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 5 | 2012 | 112 | 0.180 |
Why?
| | Anesthetics, Intravenous | 2 | 2016 | 46 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 148 | 0.170 |
Why?
| | Infant | 11 | 2024 | 9005 | 0.170 |
Why?
| | Pyridines | 2 | 2017 | 478 | 0.170 |
Why?
| | Marijuana Abuse | 1 | 2023 | 233 | 0.170 |
Why?
| | Organic Anion Transporters | 2 | 2011 | 16 | 0.170 |
Why?
| | Microspheres | 2 | 2020 | 131 | 0.170 |
Why?
| | Glutamic Acid | 2 | 2018 | 235 | 0.170 |
Why?
| | Avoidance Learning | 2 | 2024 | 71 | 0.170 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 120 | 0.170 |
Why?
| | Coronary Restenosis | 2 | 2010 | 21 | 0.170 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 402 | 0.170 |
Why?
| | Keratosis | 1 | 2020 | 16 | 0.170 |
Why?
| | Cardiomyopathies | 1 | 2024 | 339 | 0.170 |
Why?
| | Lactones | 1 | 2000 | 55 | 0.170 |
Why?
| | Losartan | 1 | 2000 | 14 | 0.170 |
Why?
| | Complement Activation | 3 | 2018 | 385 | 0.170 |
Why?
| | Opiate Substitution Treatment | 1 | 2021 | 136 | 0.170 |
Why?
| | Tetrazoles | 1 | 2000 | 38 | 0.160 |
Why?
| | Postoperative Complications | 5 | 2018 | 2475 | 0.160 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 15 | 0.160 |
Why?
| | Mental Disorders | 2 | 2021 | 1026 | 0.160 |
Why?
| | Volatilization | 1 | 2019 | 55 | 0.160 |
Why?
| | Amygdala | 3 | 2024 | 192 | 0.160 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2017 | 119 | 0.160 |
Why?
| | Reference Standards | 5 | 2016 | 176 | 0.160 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2101 | 0.160 |
Why?
| | Milk, Human | 1 | 2021 | 151 | 0.160 |
Why?
| | Adenosine | 4 | 2017 | 225 | 0.160 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 76 | 0.160 |
Why?
| | Brain Chemistry | 1 | 2000 | 118 | 0.160 |
Why?
| | Angiotensin II | 1 | 2000 | 95 | 0.160 |
Why?
| | Carotid Arteries | 2 | 2018 | 196 | 0.160 |
Why?
| | Case-Control Studies | 7 | 2025 | 3383 | 0.160 |
Why?
| | Age Factors | 7 | 2018 | 3150 | 0.160 |
Why?
| | Astrocytes | 4 | 2011 | 197 | 0.160 |
Why?
| | Perfusion | 6 | 2017 | 197 | 0.160 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 112 | 0.160 |
Why?
| | Fentanyl | 2 | 2011 | 81 | 0.160 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 84 | 0.160 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 15 | 0.160 |
Why?
| | Spine | 1 | 2021 | 160 | 0.160 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 87 | 0.160 |
Why?
| | Leukotrienes | 1 | 2019 | 37 | 0.160 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2017 | 99 | 0.160 |
Why?
| | Vascular Diseases | 2 | 2019 | 240 | 0.150 |
Why?
| | Coronary Care Units | 1 | 2018 | 18 | 0.150 |
Why?
| | Bilirubin | 3 | 1995 | 95 | 0.150 |
Why?
| | Taurine | 1 | 2019 | 43 | 0.150 |
Why?
| | Methadone | 1 | 2020 | 92 | 0.150 |
Why?
| | Imidazoles | 1 | 2000 | 235 | 0.150 |
Why?
| | Cystathionine beta-Synthase | 1 | 2019 | 69 | 0.150 |
Why?
| | Treatment Outcome | 11 | 2021 | 10232 | 0.150 |
Why?
| | Caspase 3 | 2 | 2017 | 244 | 0.150 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 177 | 0.150 |
Why?
| | DNA Damage | 2 | 2019 | 383 | 0.150 |
Why?
| | Systems Biology | 1 | 2019 | 60 | 0.150 |
Why?
| | Legislation, Drug | 1 | 1999 | 77 | 0.150 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 23 | 0.150 |
Why?
| | Complement Factor D | 1 | 2018 | 30 | 0.150 |
Why?
| | Phosphocreatine | 3 | 2004 | 43 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2020 | 209 | 0.150 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 315 | 0.150 |
Why?
| | Homocystinuria | 1 | 2019 | 70 | 0.150 |
Why?
| | Naphthalenes | 1 | 1998 | 57 | 0.150 |
Why?
| | Creatinine | 5 | 2022 | 489 | 0.150 |
Why?
| | Iohexol | 1 | 2018 | 19 | 0.150 |
Why?
| | Aged | 16 | 2021 | 22063 | 0.140 |
Why?
| | Excipients | 1 | 2018 | 52 | 0.140 |
Why?
| | Vascular Access Devices | 1 | 2018 | 26 | 0.140 |
Why?
| | Reference Values | 4 | 2013 | 795 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 37 | 0.140 |
Why?
| | Phospholipids | 5 | 2013 | 215 | 0.140 |
Why?
| | Lysophosphatidylcholines | 1 | 2017 | 21 | 0.140 |
Why?
| | Genotype | 5 | 2019 | 1827 | 0.140 |
Why?
| | Phenylpropionates | 1 | 2017 | 18 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 195 | 0.140 |
Why?
| | Enzyme Activation | 2 | 2017 | 806 | 0.140 |
Why?
| | Glucuronides | 2 | 2022 | 18 | 0.140 |
Why?
| | Sex Factors | 3 | 2019 | 1966 | 0.140 |
Why?
| | Anti-Bacterial Agents | 5 | 1996 | 1708 | 0.140 |
Why?
| | Cells, Cultured | 10 | 2017 | 4087 | 0.140 |
Why?
| | Complement Factor B | 1 | 2018 | 109 | 0.140 |
Why?
| | Terbutaline | 1 | 2017 | 8 | 0.140 |
Why?
| | Endothelins | 1 | 2017 | 62 | 0.140 |
Why?
| | Acute Kidney Injury | 2 | 2018 | 789 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 4 | 2014 | 885 | 0.140 |
Why?
| | Pyridazines | 1 | 2017 | 54 | 0.140 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 109 | 0.140 |
Why?
| | Enzyme Stability | 1 | 2017 | 69 | 0.140 |
Why?
| | Guanosine | 1 | 2017 | 41 | 0.140 |
Why?
| | Maternal Exposure | 1 | 2019 | 177 | 0.140 |
Why?
| | Complement Factor H | 1 | 2018 | 73 | 0.140 |
Why?
| | Endothelium | 2 | 2014 | 120 | 0.140 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2017 | 186 | 0.130 |
Why?
| | Single-Blind Method | 1 | 2017 | 269 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 150 | 0.130 |
Why?
| | Air Pollution | 1 | 2019 | 218 | 0.130 |
Why?
| | Quality Control | 4 | 2021 | 161 | 0.130 |
Why?
| | Glutathione | 4 | 2009 | 349 | 0.130 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 203 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 183 | 0.130 |
Why?
| | Pregnancy Complications | 1 | 2021 | 493 | 0.130 |
Why?
| | Plasma | 2 | 2017 | 206 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 276 | 0.130 |
Why?
| | Ischemia | 2 | 2012 | 405 | 0.130 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 69 | 0.130 |
Why?
| | Necrosis | 1 | 2017 | 234 | 0.130 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.130 |
Why?
| | Gastrectomy | 1 | 2017 | 102 | 0.130 |
Why?
| | Vitamin D | 1 | 2019 | 379 | 0.130 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2016 | 646 | 0.130 |
Why?
| | Mutation | 2 | 2022 | 3702 | 0.120 |
Why?
| | Inflammation | 8 | 2022 | 2741 | 0.120 |
Why?
| | Myocardial Reperfusion Injury | 3 | 2007 | 129 | 0.120 |
Why?
| | Laboratory Proficiency Testing | 1 | 2015 | 9 | 0.120 |
Why?
| | Bone Marrow Transplantation | 2 | 1996 | 277 | 0.120 |
Why?
| | Arginine | 1 | 2017 | 262 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 228 | 0.120 |
Why?
| | Propofol | 1 | 2016 | 63 | 0.120 |
Why?
| | Tunica Intima | 2 | 2010 | 84 | 0.120 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 180 | 0.120 |
Why?
| | Depression | 2 | 2021 | 1321 | 0.120 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 75 | 0.120 |
Why?
| | Sex Characteristics | 3 | 2023 | 734 | 0.120 |
Why?
| | Reperfusion Injury | 1 | 2018 | 272 | 0.120 |
Why?
| | Hepatocytes | 2 | 2006 | 215 | 0.120 |
Why?
| | Cerebral Cortex | 2 | 2024 | 439 | 0.120 |
Why?
| | HIV Infections | 3 | 2019 | 2729 | 0.120 |
Why?
| | Aerosols | 1 | 2016 | 171 | 0.120 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 62 | 0.120 |
Why?
| | Larva | 1 | 2016 | 215 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2023 | 1022 | 0.110 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 97 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 339 | 0.110 |
Why?
| | Cholestasis | 3 | 1995 | 231 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 406 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1559 | 0.110 |
Why?
| | Benzamides | 3 | 2009 | 203 | 0.110 |
Why?
| | United States | 5 | 2020 | 13865 | 0.110 |
Why?
| | Specimen Handling | 1 | 2015 | 163 | 0.110 |
Why?
| | Extinction, Psychological | 1 | 2015 | 89 | 0.110 |
Why?
| | Piperidines | 1 | 2016 | 200 | 0.110 |
Why?
| | Pharmacokinetics | 3 | 2020 | 29 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.110 |
Why?
| | C-Reactive Protein | 3 | 2022 | 400 | 0.110 |
Why?
| | Tidal Volume | 1 | 2014 | 85 | 0.110 |
Why?
| | Rabbits | 3 | 2017 | 769 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 606 | 0.110 |
Why?
| | Prognosis | 4 | 2018 | 3772 | 0.110 |
Why?
| | Carbon Isotopes | 2 | 2024 | 127 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| | Mental Recall | 1 | 2015 | 191 | 0.110 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2006 | 182 | 0.110 |
Why?
| | Altitude Sickness | 2 | 2006 | 141 | 0.110 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 78 | 0.110 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 22 | 0.110 |
Why?
| | Apoptosis | 4 | 2017 | 2488 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2015 | 261 | 0.110 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 39 | 0.110 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2013 | 37 | 0.110 |
Why?
| | Receptor, Adenosine A2B | 1 | 2013 | 43 | 0.110 |
Why?
| | Fatty Acids | 2 | 2014 | 427 | 0.110 |
Why?
| | Drug Resistance, Multiple | 3 | 2002 | 25 | 0.110 |
Why?
| | Brachial Artery | 3 | 2019 | 192 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 105 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1132 | 0.100 |
Why?
| | Adenosine Triphosphate | 4 | 2004 | 475 | 0.100 |
Why?
| | Coronary Artery Disease | 2 | 2010 | 677 | 0.100 |
Why?
| | Schizophrenia | 1 | 2017 | 425 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 54 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1770 | 0.100 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 56 | 0.100 |
Why?
| | Iron | 2 | 2010 | 283 | 0.100 |
Why?
| | Ion Transport | 1 | 2012 | 62 | 0.100 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 68 | 0.100 |
Why?
| | Calibration | 4 | 2019 | 140 | 0.100 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 509 | 0.100 |
Why?
| | Endothelial Cells | 2 | 2018 | 739 | 0.100 |
Why?
| | Graft vs Host Disease | 2 | 2000 | 240 | 0.100 |
Why?
| | Retrospective Studies | 9 | 2020 | 14532 | 0.100 |
Why?
| | Oncogene Proteins | 1 | 2012 | 54 | 0.100 |
Why?
| | Gluconeogenesis | 1 | 2012 | 78 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 566 | 0.100 |
Why?
| | Models, Theoretical | 3 | 2025 | 548 | 0.100 |
Why?
| | Integrins | 1 | 2012 | 93 | 0.100 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2012 | 94 | 0.100 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 17 | 0.100 |
Why?
| | Fibronectins | 1 | 2012 | 126 | 0.100 |
Why?
| | Monitoring, Physiologic | 3 | 2012 | 261 | 0.100 |
Why?
| | Swine, Miniature | 2 | 2010 | 81 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 211 | 0.090 |
Why?
| | Down Syndrome | 1 | 2018 | 471 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Hot Flashes | 1 | 2012 | 82 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 277 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 526 | 0.090 |
Why?
| | Lung | 9 | 2013 | 3928 | 0.090 |
Why?
| | Blood Volume | 1 | 2011 | 61 | 0.090 |
Why?
| | Association Learning | 1 | 2012 | 62 | 0.090 |
Why?
| | Vagus Nerve | 1 | 2012 | 86 | 0.090 |
Why?
| | Disease Progression | 4 | 2022 | 2628 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 157 | 0.090 |
Why?
| | Internet | 1 | 2015 | 620 | 0.090 |
Why?
| | Ritonavir | 1 | 2011 | 73 | 0.090 |
Why?
| | Morphine Derivatives | 1 | 2011 | 18 | 0.090 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 22 | 0.090 |
Why?
| | Cell Cycle | 2 | 2011 | 583 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2013 | 315 | 0.090 |
Why?
| | Consumer Product Safety | 1 | 2011 | 32 | 0.090 |
Why?
| | Survival Analysis | 2 | 2012 | 1270 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 818 | 0.090 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 259 | 0.090 |
Why?
| | Methylation | 1 | 2011 | 228 | 0.090 |
Why?
| | Tachyphylaxis | 1 | 2010 | 4 | 0.090 |
Why?
| | Structure-Activity Relationship | 5 | 2013 | 548 | 0.090 |
Why?
| | Cholinergic Agents | 1 | 2010 | 15 | 0.090 |
Why?
| | Phenotype | 3 | 2022 | 3058 | 0.090 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 763 | 0.080 |
Why?
| | Needs Assessment | 1 | 2012 | 355 | 0.080 |
Why?
| | Verapamil | 2 | 2009 | 41 | 0.080 |
Why?
| | Trigonella | 1 | 2010 | 1 | 0.080 |
Why?
| | Graft Occlusion, Vascular | 2 | 2017 | 41 | 0.080 |
Why?
| | Neoplasms | 2 | 2016 | 2450 | 0.080 |
Why?
| | Giant Cells | 1 | 2010 | 23 | 0.080 |
Why?
| | Sensation | 1 | 2010 | 51 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 284 | 0.080 |
Why?
| | Respiration, Artificial | 1 | 2014 | 615 | 0.080 |
Why?
| | Tablets, Enteric-Coated | 2 | 2007 | 6 | 0.080 |
Why?
| | Peptide Mapping | 1 | 2010 | 64 | 0.080 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 181 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 464 | 0.080 |
Why?
| | Micromonosporaceae | 1 | 2009 | 1 | 0.080 |
Why?
| | Antigens, Plant | 1 | 2010 | 48 | 0.080 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2012 | 153 | 0.080 |
Why?
| | Albuminuria | 1 | 2010 | 183 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 91 | 0.080 |
Why?
| | Conditioning, Classical | 2 | 2024 | 105 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 209 | 0.080 |
Why?
| | Diclofenac | 1 | 2009 | 15 | 0.080 |
Why?
| | Cell Death | 1 | 2011 | 352 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 443 | 0.080 |
Why?
| | Infusions, Subcutaneous | 1 | 2009 | 21 | 0.080 |
Why?
| | Administration, Intravenous | 2 | 2021 | 142 | 0.080 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 5 | 2000 | 10 | 0.080 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 381 | 0.080 |
Why?
| | Loperamide | 1 | 2009 | 11 | 0.080 |
Why?
| | Surface Properties | 3 | 2019 | 400 | 0.080 |
Why?
| | Radioimmunoassay | 6 | 1996 | 173 | 0.080 |
Why?
| | Cross Reactions | 2 | 2007 | 132 | 0.080 |
Why?
| | Oncogenes | 1 | 2009 | 110 | 0.080 |
Why?
| | Creatine | 2 | 2006 | 58 | 0.080 |
Why?
| | Aorta | 2 | 2003 | 407 | 0.080 |
Why?
| | Nanoparticles | 1 | 2013 | 376 | 0.080 |
Why?
| | Rats, Inbred Strains | 3 | 2015 | 367 | 0.080 |
Why?
| | Species Specificity | 2 | 2008 | 568 | 0.070 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2006 | 63 | 0.070 |
Why?
| | Lymphocyte Activation | 6 | 2003 | 1109 | 0.070 |
Why?
| | Drug Evaluation | 2 | 2000 | 82 | 0.070 |
Why?
| | Automation | 2 | 2016 | 81 | 0.070 |
Why?
| | Kidney Medulla | 1 | 2008 | 34 | 0.070 |
Why?
| | Guinea Pigs | 1 | 2008 | 157 | 0.070 |
Why?
| | Kidney Tubules, Collecting | 1 | 2008 | 30 | 0.070 |
Why?
| | Taste | 2 | 2024 | 225 | 0.070 |
Why?
| | Hydroxybutyrates | 2 | 2005 | 14 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 257 | 0.070 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 140 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2009 | 1029 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 14 | 0.070 |
Why?
| | Rats, Inbred F344 | 1 | 2008 | 256 | 0.070 |
Why?
| | Sulfonamides | 1 | 2011 | 497 | 0.070 |
Why?
| | Macaca mulatta | 1 | 2008 | 150 | 0.070 |
Why?
| | Delayed-Action Preparations | 3 | 2017 | 172 | 0.070 |
Why?
| | Drug Combinations | 3 | 2024 | 329 | 0.070 |
Why?
| | Allergens | 1 | 2011 | 385 | 0.070 |
Why?
| | Enzymes | 1 | 2008 | 67 | 0.070 |
Why?
| | Switzerland | 1 | 2007 | 36 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 329 | 0.070 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2011 | 123 | 0.070 |
Why?
| | Myocardial Infarction | 2 | 2007 | 1018 | 0.070 |
Why?
| | Emulsions | 5 | 2016 | 51 | 0.070 |
Why?
| | Acute Disease | 6 | 2005 | 975 | 0.070 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2062 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 275 | 0.070 |
Why?
| | NAD | 2 | 2004 | 74 | 0.070 |
Why?
| | Serum Albumin | 3 | 2019 | 149 | 0.070 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2013 | 133 | 0.070 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2007 | 74 | 0.070 |
Why?
| | Narcotic Antagonists | 1 | 2008 | 164 | 0.070 |
Why?
| | Follow-Up Studies | 5 | 2018 | 4891 | 0.070 |
Why?
| | Fetus | 2 | 2021 | 780 | 0.060 |
Why?
| | Caco-2 Cells | 3 | 2003 | 76 | 0.060 |
Why?
| | Liver Diseases | 2 | 2024 | 291 | 0.060 |
Why?
| | Immune Tolerance | 3 | 2017 | 356 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1061 | 0.060 |
Why?
| | Cardiotonic Agents | 1 | 2007 | 126 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 382 | 0.060 |
Why?
| | Organ Preservation Solutions | 1 | 2006 | 45 | 0.060 |
Why?
| | Lactic Acid | 4 | 2009 | 304 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 1931 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 546 | 0.060 |
Why?
| | Macaca | 1 | 2006 | 54 | 0.060 |
Why?
| | Body Weight | 5 | 2001 | 941 | 0.060 |
Why?
| | Nitric Oxide | 3 | 2017 | 897 | 0.060 |
Why?
| | Food-Drug Interactions | 1 | 2005 | 9 | 0.060 |
Why?
| | Growth Inhibitors | 1 | 2005 | 42 | 0.060 |
Why?
| | Technology, Pharmaceutical | 1 | 2005 | 20 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 338 | 0.060 |
Why?
| | Lactates | 1 | 2005 | 85 | 0.060 |
Why?
| | Organ Preservation | 1 | 2006 | 94 | 0.060 |
Why?
| | Methylamines | 1 | 2005 | 30 | 0.060 |
Why?
| | Ships | 1 | 1985 | 5 | 0.060 |
Why?
| | Posture | 1 | 2006 | 174 | 0.060 |
Why?
| | Deuterium | 1 | 2005 | 87 | 0.060 |
Why?
| | Phosphorylation | 5 | 2012 | 1714 | 0.060 |
Why?
| | Insulin Infusion Systems | 1 | 2009 | 362 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 49 | 0.060 |
Why?
| | Hot Temperature | 2 | 2012 | 369 | 0.060 |
Why?
| | Organ Size | 3 | 2015 | 455 | 0.060 |
Why?
| | Iliac Artery | 2 | 2017 | 55 | 0.060 |
Why?
| | Hippocampus | 1 | 2010 | 844 | 0.060 |
Why?
| | Streptozocin | 1 | 2005 | 20 | 0.060 |
Why?
| | Colorado | 5 | 2021 | 4403 | 0.060 |
Why?
| | Risk Factors | 4 | 2021 | 9779 | 0.060 |
Why?
| | CD55 Antigens | 1 | 2005 | 30 | 0.060 |
Why?
| | Echocardiography | 2 | 2024 | 635 | 0.060 |
Why?
| | Triglycerides | 3 | 2011 | 514 | 0.060 |
Why?
| | Paraplegia | 1 | 1985 | 57 | 0.060 |
Why?
| | Warfarin | 1 | 2006 | 147 | 0.060 |
Why?
| | Complement Inactivator Proteins | 1 | 2005 | 41 | 0.060 |
Why?
| | Drug Design | 1 | 2005 | 157 | 0.060 |
Why?
| | Steroids | 2 | 2005 | 158 | 0.060 |
Why?
| | Consensus | 2 | 2019 | 622 | 0.060 |
Why?
| | Troleandomycin | 3 | 1999 | 16 | 0.060 |
Why?
| | Vasodilation | 2 | 2018 | 476 | 0.060 |
Why?
| | Saccharin | 1 | 2024 | 6 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 751 | 0.060 |
Why?
| | Stress, Psychological | 2 | 2025 | 1067 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 70 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2007 | 1075 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2013 | 988 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2005 | 122 | 0.060 |
Why?
| | Calcineurin | 2 | 2004 | 103 | 0.060 |
Why?
| | Propylene Glycols | 1 | 2024 | 27 | 0.060 |
Why?
| | Cholesterol, HDL | 2 | 2013 | 197 | 0.060 |
Why?
| | Trimethylsilyl Compounds | 1 | 2004 | 4 | 0.060 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.060 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 10 | 0.050 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 24 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 32 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 2875 | 0.050 |
Why?
| | Antitubercular Agents | 1 | 2005 | 200 | 0.050 |
Why?
| | DNA | 2 | 2009 | 1400 | 0.050 |
Why?
| | Insulin | 3 | 2009 | 2313 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 92 | 0.050 |
Why?
| | Analysis of Variance | 2 | 1997 | 1286 | 0.050 |
Why?
| | Protein Binding | 3 | 2018 | 2121 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2004 | 187 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 139 | 0.050 |
Why?
| | Midazolam | 1 | 2003 | 55 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2009 | 837 | 0.050 |
Why?
| | Fibrinolytic Agents | 1 | 2006 | 262 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 2225 | 0.050 |
Why?
| | Tumor Cells, Cultured | 3 | 2001 | 931 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2005 | 199 | 0.050 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2010 | 260 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5429 | 0.050 |
Why?
| | Altitude | 3 | 2017 | 462 | 0.050 |
Why?
| | NADP | 2 | 1994 | 47 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 2 | 2018 | 37 | 0.050 |
Why?
| | Pancreas Transplantation | 1 | 2003 | 75 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 149 | 0.050 |
Why?
| | Cognition | 2 | 2023 | 1125 | 0.050 |
Why?
| | Leukocytes | 1 | 2024 | 304 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2024 | 160 | 0.050 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2000 | 107 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 27 | 0.050 |
Why?
| | Ketoconazole | 2 | 1999 | 4 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5078 | 0.050 |
Why?
| | Oligodendroglia | 1 | 2024 | 167 | 0.050 |
Why?
| | Sports | 1 | 1985 | 225 | 0.050 |
Why?
| | Oral Mucosal Absorption | 1 | 2021 | 1 | 0.050 |
Why?
| | Hepatobiliary Elimination | 1 | 2021 | 1 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 527 | 0.050 |
Why?
| | Reperfusion | 1 | 2002 | 38 | 0.050 |
Why?
| | Administration, Sublingual | 1 | 2021 | 10 | 0.050 |
Why?
| | Wine | 1 | 2001 | 11 | 0.050 |
Why?
| | Drug Dosage Calculations | 1 | 2021 | 22 | 0.050 |
Why?
| | Plant Preparations | 1 | 2002 | 32 | 0.050 |
Why?
| | Drug Overdose | 1 | 2006 | 326 | 0.050 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2001 | 55 | 0.050 |
Why?
| | Biological Transport | 2 | 2003 | 405 | 0.050 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 108 | 0.050 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 298 | 0.050 |
Why?
| | Psychotropic Drugs | 1 | 2002 | 69 | 0.050 |
Why?
| | Cell Survival | 3 | 2012 | 1084 | 0.050 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 109 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 80 | 0.040 |
Why?
| | Behavior, Animal | 1 | 2024 | 495 | 0.040 |
Why?
| | Glomerular Mesangium | 2 | 1991 | 20 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 69 | 0.040 |
Why?
| | Microchemistry | 3 | 2000 | 20 | 0.040 |
Why?
| | Haplotypes | 2 | 2013 | 474 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 177 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 424 | 0.040 |
Why?
| | Membrane Glycoproteins | 2 | 2001 | 477 | 0.040 |
Why?
| | Gene Silencing | 2 | 2012 | 189 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 1950 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 49 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2013 | 330 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2020 | 1684 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 227 | 0.040 |
Why?
| | Aorta, Abdominal | 1 | 2000 | 43 | 0.040 |
Why?
| | Pyrazoles | 1 | 2004 | 403 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2000 | 9 | 0.040 |
Why?
| | LLC-PK1 Cells | 1 | 2000 | 18 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 266 | 0.040 |
Why?
| | Antimetabolites | 1 | 2000 | 23 | 0.040 |
Why?
| | Reward | 1 | 2022 | 243 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 143 | 0.040 |
Why?
| | Logistic Models | 2 | 2022 | 1983 | 0.040 |
Why?
| | Risk Assessment | 3 | 2018 | 3255 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 458 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 21 | 0.040 |
Why?
| | Blood Glucose | 2 | 2009 | 2071 | 0.040 |
Why?
| | Heart | 1 | 2003 | 643 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 403 | 0.040 |
Why?
| | Transplantation, Heterotopic | 1 | 1999 | 18 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2020 | 171 | 0.040 |
Why?
| | Rats, Inbred BN | 4 | 2000 | 58 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 82 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 57 | 0.040 |
Why?
| | Citrus | 1 | 1999 | 6 | 0.040 |
Why?
| | Antibodies, Monoclonal | 3 | 2001 | 1366 | 0.040 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 147 | 0.040 |
Why?
| | Attention | 1 | 2023 | 439 | 0.040 |
Why?
| | K562 Cells | 2 | 2009 | 85 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1211 | 0.040 |
Why?
| | Cytokines | 3 | 2014 | 2018 | 0.040 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 180 | 0.040 |
Why?
| | Epithelium | 1 | 2000 | 311 | 0.040 |
Why?
| | Antigens, CD | 1 | 2001 | 485 | 0.040 |
Why?
| | Individuality | 1 | 2000 | 159 | 0.040 |
Why?
| | Beverages | 1 | 1999 | 68 | 0.040 |
Why?
| | Maternal Age | 1 | 2019 | 125 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Analgesics | 1 | 2020 | 194 | 0.040 |
Why?
| | Amides | 1 | 1999 | 91 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 70 | 0.040 |
Why?
| | Europe | 1 | 1999 | 362 | 0.040 |
Why?
| | Hypertension | 1 | 2007 | 1235 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 153 | 0.040 |
Why?
| | Ultrafiltration | 1 | 2018 | 28 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2014 | 1158 | 0.040 |
Why?
| | Drug Liberation | 1 | 2018 | 30 | 0.040 |
Why?
| | Sus scrofa | 1 | 2018 | 46 | 0.040 |
Why?
| | Nitriles | 1 | 1999 | 169 | 0.040 |
Why?
| | F2-Isoprostanes | 2 | 2009 | 20 | 0.040 |
Why?
| | Solutions | 2 | 2016 | 151 | 0.040 |
Why?
| | Ions | 1 | 2018 | 66 | 0.040 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 75 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 374 | 0.040 |
Why?
| | Serum Albumin, Bovine | 1 | 2018 | 63 | 0.040 |
Why?
| | Bioreactors | 1 | 2018 | 42 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 1998 | 118 | 0.040 |
Why?
| | Nifedipine | 1 | 1997 | 29 | 0.040 |
Why?
| | Urea | 1 | 2018 | 76 | 0.040 |
Why?
| | Bronchi | 1 | 1999 | 249 | 0.040 |
Why?
| | Weight Gain | 1 | 2001 | 510 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1998 | 101 | 0.030 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 417 | 0.030 |
Why?
| | Food Hypersensitivity | 2 | 2011 | 177 | 0.030 |
Why?
| | Anxiety | 1 | 2024 | 976 | 0.030 |
Why?
| | Intestines | 1 | 2000 | 350 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 2011 | 202 | 0.030 |
Why?
| | Postoperative Care | 1 | 1999 | 244 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 309 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2017 | 64 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 179 | 0.030 |
Why?
| | Stroke | 1 | 2006 | 1071 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2055 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 151 | 0.030 |
Why?
| | Archaeal Proteins | 1 | 2017 | 48 | 0.030 |
Why?
| | Cholesterol, VLDL | 1 | 1996 | 5 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2008 | 146 | 0.030 |
Why?
| | Schizophrenic Psychology | 1 | 2017 | 94 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 349 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Temperature | 1 | 2000 | 635 | 0.030 |
Why?
| | Hydrolysis | 2 | 2013 | 186 | 0.030 |
Why?
| | Pharmacogenomic Testing | 1 | 2017 | 61 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2827 | 0.030 |
Why?
| | Cytochrome P-450 CYP2E1 | 1 | 1996 | 25 | 0.030 |
Why?
| | Catheterization | 1 | 2017 | 176 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 627 | 0.030 |
Why?
| | Cell Count | 2 | 2013 | 318 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 614 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2010 | 2421 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 74 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 328 | 0.030 |
Why?
| | Anterior Chamber | 1 | 1996 | 22 | 0.030 |
Why?
| | Anesthesia, Intravenous | 1 | 2016 | 15 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2269 | 0.030 |
Why?
| | Materials Testing | 1 | 2018 | 349 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 541 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 42 | 0.030 |
Why?
| | Bromocriptine | 1 | 1996 | 29 | 0.030 |
Why?
| | Nonlinear Dynamics | 1 | 2016 | 88 | 0.030 |
Why?
| | Gastric Mucosa | 1 | 1996 | 53 | 0.030 |
Why?
| | Duodenum | 1 | 1996 | 74 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 364 | 0.030 |
Why?
| | Nicotinic Agonists | 1 | 2017 | 121 | 0.030 |
Why?
| | Health Policy | 1 | 1999 | 350 | 0.030 |
Why?
| | Syringes | 1 | 2016 | 43 | 0.030 |
Why?
| | Incidence | 2 | 2018 | 2643 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 620 | 0.030 |
Why?
| | Artificial Organs | 1 | 1995 | 2 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 473 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2007 | 1891 | 0.030 |
Why?
| | Estradiol | 1 | 2019 | 492 | 0.030 |
Why?
| | Neuroglia | 1 | 1996 | 166 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 42 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 385 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 408 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 318 | 0.030 |
Why?
| | Citric Acid Cycle | 2 | 2010 | 55 | 0.030 |
Why?
| | Asialoglycoproteins | 1 | 1995 | 2 | 0.030 |
Why?
| | Safety | 1 | 2017 | 335 | 0.030 |
Why?
| | Rhodamines | 1 | 1995 | 18 | 0.030 |
Why?
| | Extracellular Matrix | 2 | 1996 | 506 | 0.030 |
Why?
| | Heat-Shock Proteins | 2 | 2007 | 137 | 0.030 |
Why?
| | alpha-Fetoproteins | 1 | 1995 | 42 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 23 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 18 | 0.030 |
Why?
| | Oxides | 1 | 1995 | 41 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 391 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 376 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 236 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 354 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 1996 | 349 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 869 | 0.030 |
Why?
| | Pain Measurement | 2 | 2010 | 507 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1995 | 46 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 83 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 851 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 65 | 0.030 |
Why?
| | Kidney Function Tests | 3 | 2006 | 152 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 88 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 673 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 437 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 118 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 12 | 0.030 |
Why?
| | Nevirapine | 1 | 2013 | 17 | 0.030 |
Why?
| | Benzoxazines | 1 | 2013 | 30 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2013 | 89 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 1999 | 84 | 0.030 |
Why?
| | Alkynes | 1 | 2013 | 56 | 0.030 |
Why?
| | Phospholipases | 1 | 2013 | 13 | 0.030 |
Why?
| | Peripheral Arterial Disease | 1 | 2020 | 458 | 0.030 |
Why?
| | Mannitol | 2 | 2006 | 38 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2271 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2013 | 22 | 0.030 |
Why?
| | Cognition Disorders | 1 | 2017 | 505 | 0.030 |
Why?
| | Models, Molecular | 2 | 2013 | 1487 | 0.030 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 11 | 0.030 |
Why?
| | bcl-2-Associated X Protein | 1 | 2012 | 55 | 0.030 |
Why?
| | Mothers | 1 | 2019 | 731 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2012 | 41 | 0.020 |
Why?
| | Laparoscopy | 1 | 2017 | 446 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 381 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 649 | 0.020 |
Why?
| | Leucovorin | 1 | 2012 | 70 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 94 | 0.020 |
Why?
| | Heart Rate | 2 | 2009 | 804 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 69 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 208 | 0.020 |
Why?
| | Smoking | 1 | 2020 | 1501 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2009 | 3622 | 0.020 |
Why?
| | Vascular System Injuries | 1 | 2013 | 73 | 0.020 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 139 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 7 | 0.020 |
Why?
| | Asialoglycoprotein Receptor | 2 | 2006 | 6 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2012 | 193 | 0.020 |
Why?
| | Fear | 1 | 2015 | 333 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 27 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1094 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 190 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 167 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 773 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 31 | 0.020 |
Why?
| | Phenobarbital | 1 | 1991 | 19 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 531 | 0.020 |
Why?
| | Contrast Media | 1 | 1995 | 393 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 1991 | 22 | 0.020 |
Why?
| | Actins | 2 | 2007 | 406 | 0.020 |
Why?
| | Heart Ventricles | 2 | 2007 | 778 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 179 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 169 | 0.020 |
Why?
| | Femoral Artery | 1 | 2013 | 174 | 0.020 |
Why?
| | Darunavir | 1 | 2011 | 18 | 0.020 |
Why?
| | Dealkylation | 1 | 1991 | 3 | 0.020 |
Why?
| | Glucuronates | 1 | 1991 | 5 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 463 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 267 | 0.020 |
Why?
| | Fluorouracil | 1 | 2012 | 197 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 89 | 0.020 |
Why?
| | Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 7 | 0.020 |
Why?
| | Spectrophotometry, Infrared | 1 | 1991 | 54 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 1991 | 29 | 0.020 |
Why?
| | Centrifugation | 1 | 1991 | 30 | 0.020 |
Why?
| | Cytoskeleton | 1 | 2012 | 181 | 0.020 |
Why?
| | Immunoenzyme Techniques | 3 | 1996 | 211 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 357 | 0.020 |
Why?
| | Food Analysis | 1 | 2011 | 24 | 0.020 |
Why?
| | Alfentanil | 1 | 2010 | 3 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 956 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2544 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2011 | 108 | 0.020 |
Why?
| | Aldehydes | 1 | 1991 | 144 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 590 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2734 | 0.020 |
Why?
| | Cell Division | 3 | 2001 | 787 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2010 | 191 | 0.020 |
Why?
| | Serologic Tests | 1 | 2010 | 52 | 0.020 |
Why?
| | Protein Conformation | 1 | 2013 | 861 | 0.020 |
Why?
| | Alleles | 1 | 2013 | 843 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 306 | 0.020 |
Why?
| | Pain Perception | 1 | 2010 | 42 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 872 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 139 | 0.020 |
Why?
| | Blood | 2 | 2000 | 105 | 0.020 |
Why?
| | Proteins | 1 | 1995 | 944 | 0.020 |
Why?
| | Spinacia oleracea | 1 | 2009 | 8 | 0.020 |
Why?
| | Granuloma | 1 | 2010 | 90 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 2010 | 132 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 70 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2011 | 165 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 10 | 0.020 |
Why?
| | Serbia | 1 | 2008 | 6 | 0.020 |
Why?
| | Insulin Lispro | 1 | 2009 | 39 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2009 | 89 | 0.020 |
Why?
| | Deoxyglucose | 1 | 2009 | 52 | 0.020 |
Why?
| | Succinic Acid | 1 | 2009 | 39 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 106 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5423 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 353 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2009 | 206 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 219 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 636 | 0.020 |
Why?
| | Urinalysis | 1 | 2009 | 75 | 0.020 |
Why?
| | Osmotic Pressure | 1 | 2008 | 35 | 0.020 |
Why?
| | Saline Solution, Hypertonic | 1 | 2008 | 40 | 0.020 |
Why?
| | Naloxone | 1 | 2009 | 112 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 329 | 0.020 |
Why?
| | Monocrotaline | 1 | 2007 | 28 | 0.020 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2007 | 13 | 0.020 |
Why?
| | HIV-1 | 1 | 2013 | 839 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1935 | 0.020 |
Why?
| | Fasting | 1 | 2009 | 265 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 308 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 832 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2007 | 45 | 0.020 |
Why?
| | Prosthesis Design | 1 | 2008 | 293 | 0.020 |
Why?
| | Radiography | 2 | 2000 | 798 | 0.020 |
Why?
| | Animals, Outbred Strains | 1 | 2006 | 4 | 0.020 |
Why?
| | Technetium | 1 | 2006 | 10 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 2006 | 14 | 0.020 |
Why?
| | Cell Size | 2 | 1997 | 89 | 0.020 |
Why?
| | Systole | 1 | 2007 | 190 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1988 | 305 | 0.020 |
Why?
| | Dosage Forms | 2 | 1996 | 12 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 286 | 0.020 |
Why?
| | Serum Albumin, Human | 1 | 2006 | 6 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2006 | 37 | 0.020 |
Why?
| | Procaine | 1 | 2006 | 4 | 0.020 |
Why?
| | Raffinose | 1 | 2006 | 23 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2006 | 115 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1248 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2006 | 39 | 0.020 |
Why?
| | Insulin, Regular, Human | 1 | 2006 | 43 | 0.020 |
Why?
| | Allopurinol | 1 | 2006 | 62 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 123 | 0.020 |
Why?
| | Muscle, Smooth | 1 | 2007 | 159 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 776 | 0.020 |
Why?
| | Portal System | 1 | 2006 | 13 | 0.020 |
Why?
| | Electroencephalography | 1 | 2009 | 409 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 344 | 0.020 |
Why?
| | Insulin, Long-Acting | 1 | 2006 | 62 | 0.020 |
Why?
| | Cold Ischemia | 1 | 2006 | 30 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 952 | 0.020 |
Why?
| | Biopsy | 2 | 2000 | 1087 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 89 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2006 | 224 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2724 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2009 | 325 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2007 | 334 | 0.020 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2006 | 77 | 0.010 |
Why?
| | Escherichia coli | 1 | 2009 | 766 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2005 | 196 | 0.010 |
Why?
| | Drug Compounding | 1 | 2005 | 97 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2006 | 316 | 0.010 |
Why?
| | Travel | 1 | 2006 | 122 | 0.010 |
Why?
| | Microscopy, Electron | 2 | 1996 | 423 | 0.010 |
Why?
| | Nanostructures | 1 | 2005 | 100 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 508 | 0.010 |
Why?
| | Pain | 1 | 2010 | 788 | 0.010 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 339 | 0.010 |
Why?
| | Motor Skills | 1 | 1985 | 95 | 0.010 |
Why?
| | Adaptation, Physiological | 1 | 2008 | 520 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1031 | 0.010 |
Why?
| | Gene Expression | 1 | 2009 | 1461 | 0.010 |
Why?
| | Polymers | 1 | 2008 | 479 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2135 | 0.010 |
Why?
| | Blood Coagulation | 1 | 2006 | 239 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2561 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 231 | 0.010 |
Why?
| | Absorption | 1 | 2003 | 59 | 0.010 |
Why?
| | Stroke Volume | 1 | 2007 | 593 | 0.010 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 32 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 2003 | 78 | 0.010 |
Why?
| | NFATC Transcription Factors | 1 | 2004 | 86 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 529 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 157 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2003 | 138 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1018 | 0.010 |
Why?
| | Alanine | 1 | 2003 | 143 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1995 | 3392 | 0.010 |
Why?
| | gamma-Glutamyltransferase | 2 | 1994 | 42 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 32 | 0.010 |
Why?
| | Hospitals, University | 1 | 2003 | 179 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 192 | 0.010 |
Why?
| | Alkaline Phosphatase | 2 | 1994 | 146 | 0.010 |
Why?
| | Rhodamine 123 | 1 | 2001 | 6 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 145 | 0.010 |
Why?
| | B7-2 Antigen | 1 | 2001 | 27 | 0.010 |
Why?
| | Atrial Fibrillation | 1 | 2006 | 376 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 2001 | 34 | 0.010 |
Why?
| | Transfection | 1 | 2003 | 916 | 0.010 |
Why?
| | Calorimetry | 1 | 2001 | 65 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1722 | 0.010 |
Why?
| | Molecular Conformation | 1 | 2001 | 141 | 0.010 |
Why?
| | Quantum Theory | 1 | 2001 | 82 | 0.010 |
Why?
| | Cell Membrane | 2 | 1995 | 733 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2002 | 239 | 0.010 |
Why?
| | Coloring Agents | 1 | 2000 | 78 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1735 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 64 | 0.010 |
Why?
| | Doxorubicin | 1 | 2001 | 328 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 92 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 959 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1991 | 50 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2697 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2006 | 790 | 0.010 |
Why?
| | Diuretics, Osmotic | 1 | 1999 | 2 | 0.010 |
Why?
| | Ultrasonography | 1 | 2003 | 708 | 0.010 |
Why?
| | Crotonates | 1 | 1999 | 5 | 0.010 |
Why?
| | Toluidines | 1 | 1999 | 7 | 0.010 |
Why?
| | Remission Induction | 1 | 2000 | 274 | 0.010 |
Why?
| | Vinblastine | 1 | 1999 | 69 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2004 | 659 | 0.010 |
Why?
| | Capsules | 2 | 1990 | 42 | 0.010 |
Why?
| | Thermodynamics | 1 | 2001 | 407 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 329 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1999 | 108 | 0.010 |
Why?
| | Isoxazoles | 1 | 1999 | 54 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 1999 | 422 | 0.010 |
Why?
| | Aniline Compounds | 1 | 1999 | 97 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1999 | 515 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 1999 | 165 | 0.010 |
Why?
| | Binding Sites | 1 | 2001 | 1250 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2000 | 441 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 650 | 0.010 |
Why?
| | Cytosol | 1 | 1997 | 219 | 0.010 |
Why?
| | Tissue Donors | 1 | 2000 | 391 | 0.010 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 1996 | 2 | 0.010 |
Why?
| | Acetic Anhydrides | 1 | 1996 | 3 | 0.010 |
Why?
| | Computer Simulation | 1 | 2001 | 937 | 0.010 |
Why?
| | Azathioprine | 1 | 1996 | 50 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1438 | 0.010 |
Why?
| | Administration, Topical | 1 | 1996 | 147 | 0.010 |
Why?
| | Membrane Lipids | 1 | 1996 | 91 | 0.010 |
Why?
| | Ophthalmic Solutions | 1 | 1996 | 75 | 0.010 |
Why?
| | Acetonitriles | 1 | 1995 | 11 | 0.010 |
Why?
| | Bile Canaliculi | 1 | 1995 | 12 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1642 | 0.010 |
Why?
| | Cornea | 1 | 1996 | 122 | 0.010 |
Why?
| | Albumins | 1 | 1996 | 104 | 0.010 |
Why?
| | Antifungal Agents | 1 | 1996 | 130 | 0.010 |
Why?
| | Immunoblotting | 1 | 1995 | 303 | 0.010 |
Why?
| | Fetuins | 1 | 1995 | 2 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 1995 | 35 | 0.010 |
Why?
| | Cataract Extraction | 1 | 1996 | 97 | 0.010 |
Why?
| | Ferrosoferric Oxide | 1 | 1995 | 26 | 0.010 |
Why?
| | Cytomegalovirus Infections | 1 | 1996 | 190 | 0.010 |
Why?
| | Skin | 1 | 1999 | 724 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1994 | 172 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1996 | 325 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1994 | 184 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1995 | 454 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1614 | 0.010 |
Why?
| | Vinca Alkaloids | 1 | 1993 | 5 | 0.010 |
Why?
| | Collagen | 1 | 1996 | 436 | 0.010 |
Why?
| | Affinity Labels | 1 | 1993 | 26 | 0.010 |
Why?
| | Succinimides | 1 | 1993 | 18 | 0.010 |
Why?
| | Daunorubicin | 1 | 1993 | 26 | 0.010 |
Why?
| | Cricetulus | 1 | 1993 | 107 | 0.010 |
Why?
| | CHO Cells | 1 | 1993 | 155 | 0.010 |
Why?
| | Bile Acids and Salts | 1 | 1994 | 195 | 0.010 |
Why?
| | Cricetinae | 1 | 1993 | 280 | 0.010 |
Why?
| | Norpregnenes | 1 | 1992 | 4 | 0.010 |
Why?
| | Drug Resistance | 1 | 1993 | 163 | 0.010 |
Why?
| | Tritium | 1 | 1992 | 75 | 0.010 |
Why?
| | Water | 1 | 1995 | 442 | 0.010 |
Why?
| | Glutamate Dehydrogenase | 1 | 1991 | 4 | 0.010 |
Why?
| | Cholinesterases | 1 | 1991 | 10 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 167 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1991 | 89 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1991 | 154 | 0.010 |
Why?
| | Oils | 1 | 1990 | 19 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 1994 | 635 | 0.000 |
Why?
| | Carrier Proteins | 1 | 1993 | 740 | 0.000 |
Why?
| | Gelatin | 1 | 1988 | 42 | 0.000 |
Why?
| | Antigen-Antibody Reactions | 1 | 1987 | 54 | 0.000 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 88 | 0.000 |
Why?
| | CD3 Complex | 1 | 1987 | 102 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1987 | 707 | 0.000 |
Why?
|
|
Christians's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|